Key facts
- Notable investors include Lazio Innova.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Nurex
- ·The full record, as it builds
Funding rounds
No funding rounds for Nurex are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nurex
Developer of automated tests and diagnostic devices designed for clinical laboratories. The company offers a wide range of automated tests and diagnostic systems for screening Sars Cov-2 genes, metabolic diseases, drug levels monitoring, viral diseases and oncology and also develops fully automated robotic platforms for the identification of DNA and RNA sequences in biological samples, allowing healthcare clients and laboratories to specialize in the search to improve the performance, productivity and cost-benefit ratio of advanced diagnostic applications.
- Sector
- Healthcare
- HQ
- Sassari, Italy
- Founded
- 1995
- Employees
- 6
- Website
- nurex.it/
- Ownership
- Privately Held (backing)
Nurex doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nurex shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nurex in its N-PORT filings yet. We sweep new filings monthly.